Skip to Main Content

Paper Details

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Cardiovasc Diabetol
5
2022
Author NameAffiliation
Kenneth W MahaffeyStanford Center for Clinical Research, Stanford University
  • 1 - 1

Datasets

Release 1.2